[go: up one dir, main page]

WO2003035089A1 - Prophylactiques et remedes contre la fievre aphteuse - Google Patents

Prophylactiques et remedes contre la fievre aphteuse Download PDF

Info

Publication number
WO2003035089A1
WO2003035089A1 PCT/JP2002/010902 JP0210902W WO03035089A1 WO 2003035089 A1 WO2003035089 A1 WO 2003035089A1 JP 0210902 W JP0210902 W JP 0210902W WO 03035089 A1 WO03035089 A1 WO 03035089A1
Authority
WO
WIPO (PCT)
Prior art keywords
pineapple
foot
mouth disease
acid
preventive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/010902
Other languages
English (en)
Japanese (ja)
Inventor
Kazushige Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TANAKA-AI Co Ltd
Original Assignee
TANAKA-AI Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TANAKA-AI Co Ltd filed Critical TANAKA-AI Co Ltd
Publication of WO2003035089A1 publication Critical patent/WO2003035089A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Definitions

  • the present invention relates to a drug for preventing and / or treating foot-and-mouth disease (hereinafter, referred to as "a drug for preventing and treating foot-and-mouth disease”.
  • Foot and Mouth Di sease is an international infectious disease that causes serious damage to livestock and is widespread in all parts of the world, including Asia, Africa and South America, except in some areas.
  • foot-and-mouth disease occurred in March 2001 for the first time in 92 years.
  • the outbreak was limited to four farmers, and in September of the same year, the International Bureau of Animal Disease ( ⁇ 1E) confirmed the return of Japan's foot and mouth disease to Japan.
  • ⁇ 1E International Bureau of Animal Disease
  • FMD virus foot-and-mouth disease virus
  • An object of the present invention is to provide a prophylactic and therapeutic agent for foot and mouth disease that is easy and safe to manufacture.
  • the present inventors have conducted intensive studies to achieve the above object, and as a result, have unexpectedly found that pineapple or a processed product thereof, and dibasic acid and / or tribasic acid have an antiviral action against the BV virus. I got
  • a preventive and / or remedy for foot and mouth disease characterized by containing pineapple or a processed product thereof,
  • the processed product of pineapple is at least one type of processed product selected from the group consisting of pineapple juice, marc of pineapple juice, SH protease derived from pineapple, and dried pineapple fruit epidermis.
  • a preventive and / or therapeutic agent for foot-and-mouth disease characterized by containing dibasic acid and Z or tribasic acid
  • FIG. 1 is a view showing a specific example of cutting pineapple during canning.
  • reference numeral 1 denotes an epidermis
  • reference numeral 2 denotes a peripheral pulp
  • reference numeral 3 denotes a columnar pulp in the center
  • reference numeral 4 denotes a pulp portion
  • reference numerals 5 and 6 denote top and bottom portions.
  • Foot-and-mouth disease is an acute febrile communicable disease caused by the transmission of the BOF virus, which infects livestock such as cattle, buffaloes, pigs, sheep, goats, and most other hoofed animals, including wildlife.
  • livestock such as cattle, buffaloes, pigs, sheep, goats
  • the mortality rate is over 50% for young animals.
  • Adult mortality is only a few percent, but productivity is significantly reduced due to eating disorders and walking problems.
  • the BFO virus which causes foot-and-mouth disease, is transmitted directly and indirectly by infected animals and their contaminants. Furthermore, when the area becomes a highly polluted area, air propagation It can happen. The incubation period is 6.2 days, 10.6 days and 9.0 days for cattle, pigs and sheep, respectively.
  • the hoof disease virus is a spherical single-stranded RNA virus having a diameter of about 21 to 25 nm without an envelope, and is classified into the Genus Aphthovirus of the family Picornaviridae (Family Picornaviridae).
  • Genus Aphthovirus of the family Picornaviridae Family Picornaviridae
  • immunotypes which are conventionally called subtypes (subtypes) and can only partially be expected to have a vaccine effect.
  • Pineapple is called Ananas (scientific name: Ananas) and is an evergreen perennial of the pineapple family with a height of about 60 to 120 cm.
  • the leaves are elongated, about lm in length, and the flowers bloom about 100 to 150 densely on the stem and are pale blue-purple.
  • the stem penetrates through the center of the enlarged part and has a crown on its top.
  • a crown bud is a bud that has many leaves and is in the form of a seedling.
  • the stem has other buds such as, for example, descendant buds directly below the enlarged part, buds sucking from the middle of the stem that forms the enlarged part, and tuber buds from the lower ground.
  • Various child strains occur.
  • any part of the pineapple such as stem, bud, root and fruit may be used.
  • the pulp part that is, the base part of the small fruit arranged around the elongated stem (referred to as a flower base) is used. It is particularly preferred to use a fused enlarged part.
  • Pineapple is widely cultivated throughout the tropical and subtropical regions of the world, including Hawaii, the Philippines, Thailand, Taiwan, Hainan Island in China, and Okigami Prefecture in Japan.
  • the production area of the pineapple used in the present invention is not particularly limited.
  • pineapples there are many varieties of pineapples, and the varieties are classified into, for example, a cayenne group, a queen group, a red Spanish group, a swing group, an amarero group, and a maple urea group.
  • the variety of pineapple used in the present invention is not particularly limited. Among them, Yellow 'Mauritius and Cayenne Swarms Non-spikes are often used as raw materials for edible or juice or canned foods, and are preferred because they are easily available.
  • varieties obtained as a result of breeding improvement such as varieties with increased sugar content, such as golden 'pine and super sweet pine, and snacks and pine, which are eaten by hand, are used in the present invention. May be used.
  • An embodiment of the present invention includes an agent for preventing and treating foot-and-mouth disease containing the above-described pineapple or a processed product thereof.
  • the state of the pineapple or its processed product is not particularly limited, and may be solid, liquid, or a mixed state of a solid and a liquid.
  • the preventive and therapeutic agent for foot and mouth disease according to the present invention includes the above-mentioned agents. Pineapple may be included in the form of cuts.
  • the size of the cut product is not particularly limited as long as the agent for preventing or treating foot and mouth disease according to the present invention can be administered.
  • the processed product of the pineapple is not particularly limited, and includes all pineapples that have been subjected to some processing.
  • the processed product of pineapple includes juice or pineapple extract obtained from pineapple, or a concentrate, purified product, or dried product thereof.
  • examples of the processed pineapple include dried pineapple, dried pineapple cuts, pineapple fruit epidermis or dried products thereof, and crushed products thereof.
  • processed pineapples include the remainder after squeezing the juice, that is, marc, or its dried products, and its cut products.
  • the processed product of pineapple may be a pineapple-derived SH protease.
  • SH protease is a protease having an SH group at the active center. More specifically, examples of the pineapple-derived SH protease include bromelain. Bromelain is a mixture of enzymes derived from pineapple stems and can be easily obtained by a known method. In the present invention, a commercially available product may be used.
  • the processed product of the pineapple used in the present invention can be easily obtained by a known method. For example, pineapple juice can be obtained by crushing pineapple or a part of pineapple, preferably a pulp portion, with a crusher or the like, and then squeezing the obtained crushed material using a squeezer or the like.
  • the obtained juice may be further subjected to purification means such as centrifugation and filtration. Further, the water contained in the fruit juice may be removed by a method such as distillation and concentrated. The obtained fruit juice or concentrate may be spray-dried to obtain granules or powder.
  • the pineapple extract is extracted using a hydrophilic solvent such as water or an alcohol such as ethanol, or a solvent composed of a combination thereof at normal pressure or under pressure, at normal temperature or under heating. be able to. Extraction can also be performed using vapor (gas) of a hydrophilic solvent such as water or alcohols such as ethanol. Further, similarly to the above, the obtained extract may be further subjected to purification, concentration, spray drying and the like.
  • a hydrophilic solvent such as water or an alcohol such as ethanol
  • a solvent composed of a combination thereof at normal pressure or under pressure, at normal temperature or under heating.
  • Extraction can also be performed using vapor (gas) of a hydrophilic solvent such as water or alcohols such as ethanol.
  • the obtained extract may be further subjected to purification, concentration, spray drying and the like.
  • Dried pineapple or cut pineapple can be obtained by natural drying, or can be dried by heating under pressure or normal pressure.
  • the medium used for drying may be air or an inert gas such as nitrogen, for example, and is not particularly limited.
  • the drying temperature cannot be generally specified, for example, it is preferably about 100 ° C. or less, more preferably about 70 ° C. or less.
  • the above-mentioned dried product can be obtained by freeze-drying.
  • the dried product can also be obtained by immersing pineapple or a cut product thereof, preferably a sliced cut product, in a sugar solution.
  • the dried product thus obtained may be pulverized using a known pulverizer such as a hammer mill, a power mill or a pole mill.
  • canned pineapple is manufactured in the following process.
  • Fig. 1 shows a specific example of cutting pineapple during canning. showed that.
  • the pulp is separated into a columnar pulp 3 at the center and a portion composed of peripheral pulp 2 and epidermis 1.
  • the upper and lower portions 5 and 6 of the columnar pulp 3 are cut, and then the pulp portion 4 is cored in a pulp removing step.
  • the brown eyes remaining on the surface are removed, and the surface is cut to a predetermined thickness in the cutting process.
  • this is packed in a can, sterilized and cooled in a sealed state.
  • the part consisting of the peripheral pulp 2 and the epidermis 1 the tops 5, 6 and the pulp 4 become waste.
  • the raw material of the therapeutic / preventive agent of the present invention can be easily and inexpensively obtained by effectively utilizing the waste.
  • Another advantage is that the energy and resources required for waste disposal are saved, and the burden on the environment is reduced.
  • an embodiment of the present invention includes a preventive / treatment agent for foot-and-mouth disease containing a dibasic acid and / or a tribasic acid.
  • the dibasic acid is preferably an organic dicarboxylic acid
  • the tribasic acid is preferably an organic tricarboxylic acid.
  • organic dicarboxylic acids include saturated dicarboxylic acids such as oxalic acid, malonic acid, succinic acid, malic acid, daltaric acid, and adipic acid, unsaturated dicarboxylic acids such as maleic acid and fumaric acid, phthalic acid, isophthalic acid, and terephthalic acid.
  • Aromatic dicarboxylic acids such as acids, and organic tricarboxylic acids include citric acid, isocunic acid, ciS-aconitic acid and the like, and these can be used alone or in combination of two or more.
  • malic acid is used as the organic dicarboxylic acid
  • citric acid is used alone or as a mixture as the organic tricarboxylic acid.
  • citric acid is used as the organic dicarboxylic acid.
  • oxalic acid can be added.
  • citric acid is about 50 to 70% by weight
  • malic acid is about 20 to 40% by weight
  • it contains about 1% by weight of oxalic acid.
  • the usage ratio of the organic dicarboxylic acid, the organic tricarboxylic acid and the total organic acid such as oxalate to the whole preparation is usually 1 to 50% by weight, preferably 5 to 40% by weight.
  • pineapple or a pineapple-treated product may be used in combination with one or more selected from the group consisting of organic dicarboxylic acids and organic or tricarboxylic acids.
  • the formulations of the present invention may contain bromelain.
  • the weight ratio of organic acid to bromelain is preferably about 1: 0.01-1, more preferably about 1: 0.05-0.5.
  • a commercially available bromelain can be used.
  • Bromelain 200 GDU manufactured by Nippon Paicon Co., Ltd.
  • Kimotab S 40,000 units manufactured by Mochida Pharmaceutical Co., Ltd.
  • a dibasic acid and / or a tribasic acid may contain a saccharide.
  • the sugar include monosaccharides such as glucose, fructose, mannose, galactose, xylose, arabinose, and ribulose; disaccharides such as sucrose, trehalose, isotrehalose, and isosaccharose; and oligosaccharides.
  • monosaccharides such as glucose, fructose, mannose, galactose, xylose, arabinose, and ribulose
  • disaccharides such as sucrose, trehalose, isotrehalose, and isosaccharose
  • oligosaccharides Alternatively, two or more kinds can be used in combination.
  • glucose, sucrose, and fructose are used alone or in combination of two or more. Since pineapple contains glucose, sucrose, and fructose, it is not necessary to add pineapple or its processed product.
  • glucose, sucrose, and fructose may be used in combination with other sugars.
  • the anti-foot-and-mouth disease remedy according to the present invention may be used in combination with a vaccine inoculation, another antiviral agent such as disclosed in JP-A-7-69989, and the like.
  • the pH of the preventive / treatment drug for foot and mouth disease characterized by containing the dibasic acid and / or the tribasic acid according to the present invention is more preferably in the range of about 3.2 to 3.5. If it is less than about 3.2, side effects of pain upon injection may occur in animals, and if it is more than about 3.5, the effect as a preventive / treatment drug for foot and mouth disease may be reduced.
  • Pineapple juice is preferably used as a prophylactic or remedy for foot-and-mouth disease because the pH of the fruit juice is also about 3.2 to 3.5.
  • the agent for preventing or treating foot and mouth disease according to the present invention may be in any dosage form as long as oral or parenteral administration is conveniently performed.
  • the dosage form of the drug according to the present invention may be any drug as long as it contains (1) pineapple or its processed product, and Z or (2) dibasic acid and / or tribasic acid. , Granules, tablets, capsules, liquids for internal use, suspensions, emulsions, syrups, injections, infusions and the like.
  • the prophylactic / therapeutic agents of the present invention in the above dosage forms can be used alone or in combination depending on the symptoms.
  • the prophylactic / therapeutic agent for foot and mouth disease according to the present invention may include, if desired, known additives which can be usually used in the technical field of pharmaceutical preparations such as excipients, binders, disintegrants, lubricants, flavoring agents, and stabilizers. Can be added.
  • the prophylactic / therapeutic agent of the present invention is a solid preparation such as a capsule, tablet, powder or granule, for example, excipients such as lactose, glucose, sucrose, and mannite; Disintegrators such as starch and sodium alginate; Lubricants such as magnesium stearate and talc; Binders such as polyvinyl alcohol, hydroxypropylcellulose and gelatin; Surfactants such as fatty acid esters; Additives such as plasticizers can be included in the formulation.
  • excipients such as lactose, glucose, sucrose, and mannite
  • Disintegrators such as starch and sodium alginate
  • Lubricants such as magnesium stearate and talc
  • Binders such as polyvinyl alcohol, hydroxypropylcellulose and gelatin
  • Surfactants such as fatty acid esters
  • Additives such as plasticizers can be included in the formulation.
  • the prophylactic / therapeutic agent according to the present invention is a liquid preparation
  • sugars such as water, sucrose, sorbitol, fructose
  • glycols such as polyethylene glycol and propylene glycol
  • Additives such as preservatives such as soybean oil and soybean oil
  • P-hydroxybenzoic acid esters can be contained in the preparation.
  • the prophylactic / therapeutic agent according to the present invention may be a preparation in which the active ingredient is dissolved at the time of use.
  • the amount of organic acids such as dibasic acid, tribasic acid, and oxalic acid in the preparation is The content is about 0.001 to 20% by weight, preferably about 0.5 to 15% by weight, and more preferably about 1 to 10% by weight.
  • the prophylactic / therapeutic agent according to the present invention as described above can be easily produced by a method known per se in the field of pharmaceuticals or a conventional method.
  • the agent for preventing or treating foot-and-mouth disease according to the present invention can be applied to any animal including humans, but is particularly suitable for livestock such as cattle, buffaloes, pigs, sheep, goats, and even hooves including wild animals. It is preferably applied to mammals.
  • the route of administration of the agent for preventing or treating foot and mouth disease according to the present invention is not particularly limited, and may be either oral administration or parenteral administration.
  • the agent for preventing or treating foot-and-mouth disease according to the present invention is preferably administered orally from the viewpoint of ease of administration and the like.
  • the dose of the therapeutic agent for foot-and-mouth disease according to the present invention varies depending on the administration route, dosage form, type of animal to be administered, severity of symptoms, age, body weight, and the like, and cannot be unconditionally determined. Specifically, it is about 0.01 to 10 gZkg per day, preferably about 0.1 to 5 gZkg, more preferably about 1 to 5 g / kg per day.
  • the pineapple contained in the prophylactic / therapeutic agent of the present invention has been eaten in many countries for many years, has no toxicity, and is safe to administer to animals.
  • pineapple or a processed product thereof can prevent or treat BFO.
  • dibasic and / or tribasic acids inactivate the hoof disease virus are unknown.
  • One possible mechanism could be the donation of protons from the diacid and Z or triacid to one or all amide nitrogens of various proteins in the hoof disease virus structure. This protonation is thought to result in a net positive charge in the protein structure, which may result in repulsion between the protonated amide moieties of the macromolecular protein molecule. This is because some or all of the protein structure in 10902
  • pineapple slag dried pineapple
  • pineapple juice The safety of dried pineapple (hereinafter, referred to as pineapple slag) and pineapple juice on experimental animals and antiviral activity against foot-and-mouth disease virus were examined.
  • the test materials used in Test Examples 1 to 4 are shown below.
  • mice healthy mice (4-6 days of age and mature), rats and egrets (all obtained from the laboratory animal room of Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences)
  • Calf serum Sanitized healthy calf serum (purchased from Chengdu Huaxi Biotechnology Company, and tested negative for hoof disease)
  • Type B foot-and-mouth disease virus OPNF 11 LD 50 > 8.0
  • Indirect clotting antigen Product manufactured by Lanzhou Veterinary Research Institute, Chinese Academy of Agriculture (Lot No .: 2001826), titer 1: 2048 7.
  • Dilution solution 0.1 ml ZL PBS (pH 7.6), autoclaved, stored at room temperature
  • Pineapple slag and pineapple juice are judged to be safe if they are healthy without any fatalities and no abnormal symptoms observed when inoculated by gavage or paste into various experimental animals. I do.
  • pineapple slag and pineapple juice are considered unsafe.
  • pineapple slag and pineapple juice were diluted twice in volume with no toxicity or irritation to experimental animals such as rats, and no abnormal symptoms were observed at the inoculated site. He was healthy. Therefore, the two-fold dilutions of pineapple slag and pineapple juice samples obtained from Tanaka Ai Co., Ltd. (Hong Kong) were safe without animal irritation.
  • a type O foot-and-mouth disease virus (manufactured by Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, OPNFuL D 50 > 8.0) was weighed to prepare a 1:10 (weight ratio) suspension. After adding Benicillin-G, the mixture was left at 4 ° C for 24 hours, and then centrifuged at 4000 rpm for 15 minutes. The supernatant was taken and diluted 500-fold with phosphate buffer.
  • pineapple slag and pineapple juice were each separated using sterilized deionized water to 2, 3, 4, and 5, respectively. , 6, 7, 8, 9, 10, 11, 13, 16, 19 and 21 times by volume, and mixed with an equal volume of the above-mentioned 500-fold dilution of the hoof disease virus.
  • a group was set up containing 10% calf serum at each concentration level. Equivalent to pineapple slag or pineapple juice, the above-mentioned hoof disease virus 5 The mixture was sufficiently mixed with a 00-fold diluted solution, and reacted at room temperature of 24 ° C. for 30 minutes. These were injected into mice and rats 4 to 6 days old, respectively. Also, a virus control group and a sample blank group will be provided. After observing these animals for 7 days, judgment was made.
  • the criteria for determining the effective concentration of the antiviral effect are as follows.
  • the virus-positive control group becomes sick within 24 to 72 hours after inoculation and dies, or shows the characteristic symptoms of foot-and-mouth disease virus.
  • the experimental group ie, the group to which the mixture of the sample and the hoof disease virus was administered
  • the concentration of the sample with the highest dilution that shows 3.100% anti-foot-and-mouth disease virus activity is defined as the effective concentration of the sample.
  • pineapple slag 50 g was weighed, diluted with 50 mL of PBS, added with penicillin-1G, allowed to stand at room temperature for 10 minutes, and then centrifuged at 4000 rpm for 15 minutes. The supernatant was taken, immediately injected into several mice infected with foot-and-mouth disease at the age of 2 to 4 days, and observed for 72 hours. Thereafter, the mouse was dissected, the homogenate was diluted 6-fold with Benicillin G, left at 4 ° C for 24 hours, centrifuged, and the supernatant was inoculated into the mouse. Such an operation was repeated three times.
  • Test Examples 1 to 4 by replacing the pineapple slag and pineapple juice of Test Examples 1 to 4 with the following Formulation Examples 1 and 2 was considered.
  • the resulting aqueous preparations of Formulation Examples 1 and 2 were safe, with no irritation to animals in Test Example 1, as in pineapple slag and pineapple juice, and had anti-foot-and-mouth disease virus activity in Test Examples 2 and 3. No hoof disease virus was detected in Test Example 4.
  • the present invention provides an epoch-making preventive and remedy for foot and mouth disease, for which there has been no effective treatment and preventive means.
  • the prophylactic / therapeutic agent of the present invention is toxic and safe since it contains pineapple or a processed product thereof, and dibasic acid, dibasic acid or tribasic acid as active ingredients. Moreover, since the raw materials of natural products can be used, it is easy to obtain the raw materials, and since the dosage form of the preventive / therapeutic agent is not particularly limited, the preventive / therapeutic agent according to the present invention can be easily and inexpensively manufactured. .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des prophylactiques et/ou des remèdes contre la fièvre aphteuse pouvant être fabriqués de manière simple et se révélant surs, lesdits prophylactiques et/ou remèdes étant caractérisés en ce qu'ils contiennent des extraits d'ananas éventuellement traités.
PCT/JP2002/010902 2001-10-22 2002-10-21 Prophylactiques et remedes contre la fievre aphteuse Ceased WO2003035089A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001324055 2001-10-22
JP2001-324055 2001-10-22
JP2001-395049 2001-12-26
JP2001395049A JP2003201245A (ja) 2001-10-22 2001-12-26 口蹄疫の予防治療薬

Publications (1)

Publication Number Publication Date
WO2003035089A1 true WO2003035089A1 (fr) 2003-05-01

Family

ID=26624025

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010902 Ceased WO2003035089A1 (fr) 2001-10-22 2002-10-21 Prophylactiques et remedes contre la fievre aphteuse

Country Status (2)

Country Link
JP (1) JP2003201245A (fr)
WO (1) WO2003035089A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116209460A (zh) * 2020-06-10 2023-06-02 乌尔萨法姆药物有限责任公司 用于治疗或预防由冠状病毒引起的人或动物的病毒感染的菠萝蛋白酶、菠萝酶、木菠萝素类凝集素、来自菠萝植物茎和/或果的提取物、组合制剂、菠萝蛋白酶抑制剂、蛋白质-蛋白酶混合物和外源性非酶糖化产生的糖化菠萝酶蛋白

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5435387B2 (ja) * 2010-02-05 2014-03-05 直 岩附 難分解性リグニン含有植物粉砕微粉のリグニン分解糖化方法
JP5714869B2 (ja) * 2010-10-29 2015-05-07 丸善製薬株式会社 糖不含有パイナップル抽出物、及びその製造方法、並びにその用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11199509A (ja) * 1998-01-09 1999-07-27 Shigemi Fujisaki Ｂ型肝炎又はｃ型肝炎に対する予防治療剤
WO2001087229A2 (fr) * 2000-05-19 2001-11-22 Latwest Pharmaceuticals (Proprietary) Limited Traitement d'infections

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11199509A (ja) * 1998-01-09 1999-07-27 Shigemi Fujisaki Ｂ型肝炎又はｃ型肝炎に対する予防治療剤
WO2001087229A2 (fr) * 2000-05-19 2001-11-22 Latwest Pharmaceuticals (Proprietary) Limited Traitement d'infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KONOWALCHUK JACK ET AL.: "Antiviral effect of commercial juices and beverages", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 35, no. 6, 1978, pages 1219 - 1220, XP002962327 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116209460A (zh) * 2020-06-10 2023-06-02 乌尔萨法姆药物有限责任公司 用于治疗或预防由冠状病毒引起的人或动物的病毒感染的菠萝蛋白酶、菠萝酶、木菠萝素类凝集素、来自菠萝植物茎和/或果的提取物、组合制剂、菠萝蛋白酶抑制剂、蛋白质-蛋白酶混合物和外源性非酶糖化产生的糖化菠萝酶蛋白

Also Published As

Publication number Publication date
JP2003201245A (ja) 2003-07-18

Similar Documents

Publication Publication Date Title
Behnke et al. Developing novel anthelmintics from plant cysteine proteinases
JP2019203012A (ja) 醗酵乳製品およびその使用
JP2013094119A (ja) マラリア、ねむり病、エイズ、ｃ型肝炎を撲滅する方法、及びその装置
CN114502184A (zh) 防治冠状病毒感染的包括杜英萃取物的药物和食品组合物
JP2006524193A5 (fr)
CN101076325A (zh) 含可食用羧酸和/或其酸性盐与咖啡碱的药物组合物以及无毒瘾性咖啡
JP2008518977A (ja) アルスロスピラをベースとする組成物及びその利用
KR101853076B1 (ko) 커큐민을 포함하는 살바이러스 또는 살균용 조성물
US20070148186A1 (en) Simarouba amara and/or momordica charantia extracts for the treatment of coccidiosis in poultry
WO2003035089A1 (fr) Prophylactiques et remedes contre la fievre aphteuse
Dacasin et al. The potential use of virgin coconut oil as an adjunctive treatment for COVID-19: A review
KR101128088B1 (ko) 코로나 바이러스 감염의 예방 또는 치료용 조성물 및 ３ｃｌ 프로테아제 활성의 억제용 조성물
CN104162162B (zh) 一种抗猪口蹄疫组合物、冻干粉、制备方法及应用
JP2011116670A (ja) マラリア、ねむり病、エイズ、ｃ型肝炎を撲滅する方法、及びその装置
Lobo et al. Ethnomedicinal plants for veterinary use in gypsy communities of the northeast of Brazil
KR20110086473A (ko) 감태 추출물을 포함하는 코로나 바이러스 감염의 예방 또는 치료용 조성물 및 3ｃｌ 프로테아제 활성의 억제용 조성물
JP2012205511A (ja) マラリア、ねむり病、エイズ、ｃ型肝炎を撲滅する方法、及びその装置
JP2010195760A (ja) マラリア、ねむり病、エイズ、ｃ型肝炎を撲滅する方法、及びその装置
KR20210044762A (ko) 잣나무 잎 추출물을 포함하는 항균 조성물
KR100377813B1 (ko) 대나무 추출물을 함유하는 신규한 치료용 조성물 및 이조성물을 포함하는 치료제
Salifu et al. Serum and stress marker indices of West African dwarf goats challenged with trypanosoma evansi and then treated with artemether-lumefantrine
CN1539426A (zh) 治疗和预防sars疾病的药物
KR20130013965A (ko) 어류 세균성 병원균에 대한 항진균 및 항균 겸용 조성물
CN116036187B (zh) 一种预防鸡球虫病的复方中药及其制备方法和应用
KR20240177354A (ko) 소 로타바이러스 설사병 치료제

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AU AZ BA BB BR BY BZ CA CN CO CR CU DM DZ EC GD GE HR HU ID IL IN IS KG KR KZ LC LK LR LT LV MA MD MG MK MN MX NO NZ OM PH PL RO RU SG SI TJ TM TN TT UA US UZ VC VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase